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Purpose: Cirrhosis and its related complications
remain a prominent global health concern despite
advances in understanding and treating the disorder.
Early diagnosis and intervention strategies may reduce
the impact of cirrhosis; however, it can be difﬁcult for
initial point-of-care health care providers to identify
and refer patients with cirrhosis due to lack of
knowledge and resources. This review examines cur-
rent diagnostic strategies for cirrhosis and cirrhosis-
related complications and the potential beneﬁts of
multidisciplinary care for patients with the disorder.
Methods: A PubMed search of the medical liter-
ature was conducted to identify current diagnostic
methods and standards and ascertain the impact of
multidisciplinary care on patients with cirrhosis.
Findings: Screening of patients at risk for cirrhosis
has been recommended by several professional and
governmental organizations. Unfortunately, identiﬁca-
tion of early-stage cirrhosis remains challenging de-
spite development of novel calculations for risk (eg,
aspartate transaminase-to-platelet count ratio) that
use values from common, noninvasive laboratory tests
to determine the extent of liver disease. Abnormal
liver function test results and alterations in serum liver
enzyme markers (eg, alanine and aspartate transami-
nases) may suggest cirrhosis in patients with chronic
liver disease; however, they are not deﬁnitive. Liver
biopsy is the gold standard for diagnosis and staging
of cirrhosis, but its cost, invasiveness, and risk of
complications have prompted the development of
noninvasive tests (eg, elastography). Primary care
physicians should be aware of the signs and symptoms
of cirrhosis-related complications, particularly portal
hypertension, and refer patients to specialists for
further evaluation when warranted.
Implications: Patients at risk for cirrhosis should be
screened and the underlying etiologic factor(s) of the
liver disease treated or appropriately managed when
possible. Primary care physicians should be aware of
the signs and symptoms of cirrhosis and its related
complications and adopt a low threshold for referral1822to a specialist when the condition is suspected. An
integrated, multidisciplinary approach to care between
specialists and primary care physicians may improve
early detection of cirrhosis and its related complica-
tions and strengthen management strategies. (Clin
Ther. 2015;37:1822–1836) & 2015 The Authors.
Published by Elsevier HS Journals, Inc.
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Cirrhosis is a form of chronic liver disease (CLD)
resulting from sustained liver damage from a number
of causes, including viral infection, autoimmune disor-
ders, cholestatic and metabolic disease (eg, nonalcoholic
fatty liver disease [NAFLD]), or heavy alcohol use.1,2
Progressive ﬁbrosis (ie, scarring) of the normal liver
architecture causes increased intrahepatic resistance and
the development of portal hypertension, ultimately
leading to diminished liver function and potentially
life-threatening complications.
Cirrhosis is a major public health concern. In 2010,
it was the 12th leading cause of mortality worldwide,
responsible for 1 million deaths. Among the docu-
mented deaths from cirrhosis, etiologies were found to
be divided equally among hepatitis B viral infection,
hepatitis C viral (HCV) infection, and alcohol mis-
use.3 Consistent with worldwide statistics, in the
United States in 2010, CLD/cirrhosis was the 12th
leading cause of mortality, accounting for 31,903
deaths and representing a 3.3% increase in age-
adjusted death since 2009.4 More recent US data,
using disease-speciﬁc deﬁnitions that include other
liver-related causes of mortality (eg, hepatobiliaryVolume 37 Number 8
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gest that this ﬁgure is substantially underestimated
and that the total number of liver-related deaths
exceeds 66,000, which would place total liver-
related deaths in ninth place among leading causes
of mortality, after nephrotic syndrome, based on the
National Vital Statistics Reports of the Centers for
Disease Control and Prevention.4,5 In Europe, cirrho-
sis of the liver accounts for 1.8% of all deaths
(170,000 deaths annually).6,7 In the United Kingdom,
mortality from liver disease continued to increase
between 2001 and 2010.8 In developed countries,
the leading causes of cirrhosis are HCV infection,
alcohol misuse, and NAFLD,2,9,10 with alcohol-
related cirrhosis having a worse long-term prognosis
than non–alcohol-related cirrhosis.11 Hepatitis B viral
infection is the most common cause of cirrhosis in
developing countries.9
Despite advances in understanding the pathogene-
sis of cirrhosis and improved treatment regimens,
CLD/cirrhosis and its associated complications (eg,
portal hypertension) continue to be signiﬁcant global
health concerns. Patients with cirrhosis, a progressive
disorder, may beneﬁt from early intervention strat-
egies; unfortunately, difﬁculties in the recognition and
diagnosis of early disease and cirrhosis-related com-
plications present real challenges, especially to initial
point-of-contact health care providers such as primary
care physicians (PCPs) and nurses. The present review
highlights current diagnostic strategies for cirrhosis
and cirrhosis-related complications and discusses the
importance of a multidisciplinary approach for pa-
tients with CLD/cirrhosis.MATERIALS AND METHODS
The PubMed database was searched for English-
language articles with no time limitation (up to
October 1, 2014) using the following key words:
“diagnosis,” “cirrhosis,” “portal hypertension,”
“variceal bleed,” “ascites,” “spontaneous bacterial
peritonitis,” “hepatic encephalopathy,” “hepatorenal
syndrome,” “hepatocellular carcinoma,” “multidis-
ciplinary,” “management,” “management strategy,”
and “guidelines.” Additional relevant publications
were identiﬁed from the bibliographies of publica-
tions located through the PubMed search. Articles
not related to the aforementioned topics were
excluded.August 2015RESULTS
Approximately 695 publications were identiﬁed via
the PubMed search. Of these, 155 case reports were
excluded. Publications that focused on accepted diag-
nostic techniques for cirrhosis and cirrhosis-related
complications in terms of pathogenesis and articles
relevant to interdisciplinary management of patients
were thoroughly reviewed.
Pathogenesis and Classification of Cirrhosis
Understanding the natural history of cirrhosis can
help identify patients at highest risk for life-
threatening complications of CLD, as well as those
for whom early intervention may help favorably alter
the clinical course of the disease. Cirrhosis is a late-
stage development of ﬁbrosis of the hepatic paren-
chyma, a process that involves excessive accumulation
of extracellular matrix proteins, including collagen (ie,
scar tissue).1 Liver ﬁbrosis is the consequence of a
repeated wound-healing response to ongoing hepatic
injury (Figure 1).12,13 The onset of ﬁbrosis is usually
insidious and progresses slowly, often over decades.
Patients often remain asymptomatic until symptoms of
cirrhosis emerge. Transition from early-stage ﬁbrosis
to cirrhosis involves multiple cell types and cellular
and molecular processes, not all of which are fully
understood.14 Activation of hepatic stellate cells,
which differentiate into proliferative, ﬁbrogenic
myoﬁbroblasts, represents a pivotal event in ongoing
ﬁbrogenesis, with inﬂammation and angiogenesis also
contributing to disease progression.14,15 Changes in
the hepatic microvasculature result in increased pro-
duction of endogenous vasoconstrictors, such as en-
dothelins, and a reduced production of vasodilators,
such as nitric oxide. Cumulatively, these mechanisms
contribute to increased hepatic vascular resistance and
increased portal blood ﬂow, resulting in portal hyper-
tension and diminishing liver function.
Cirrhosis is a dynamic process that can be sub-
classiﬁed into distinct clinical stages.16 In patients with
diagnosed liver disease, progression to cirrhosis may
occur up to 15 to 20 years after diagnosis.17 Patients
diagnosed with cirrhosis are classiﬁed as having either
compensated or decompensated disease.18,19 In com-
pensated cirrhosis, the liver is still able to perform
vital functions sufﬁciently, and thus few or no clinical
symptoms are present or noticeable by the patient. In
decompensated cirrhosis, there is sufﬁcient organ
damage such that the liver is unable to perform vital1823
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Figure 1. The natural history of chronic liver disease.12 NASH ¼ nonalcoholic steatohepatitis. Reprinted by
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Clinical Therapeuticsfunctions effectively, and functional decline progresses
rapidly.18,19
Transition from compensated to decompensated
cirrhosis is marked by the development of complica-
tions, including ascites, jaundice, and esophageal
varices.18,20 Survival associated with the 2 stages
differs markedly; subjects with compensated cirrhosis
have a median survival time of 412 years, whereas
the median survival time for patients with decompen-
sated disease is o2 years.18,20,21 Rate of disease
progression was the subject of a 25-year prospective
inception study of 494 patients with compensated or
decompensated cirrhosis.20 Based on the 5 prognostic
stages ranging from 1 (compensated cirrhosis without
varices) to 5 (any second decompensating event), an
exploratory analysis found that the risk of 5-year
transition rate toward a different stage was 34.5%,
42%, 65%, and 78% for stages 1 through 4,
respectively (P o 0.0001). Mortality rates paralleled
the transition rate, with patients with more advanced
disease (eg, bleeding) experiencing a higher mortality
rate than patients with earlier stages of disease.20
These ﬁndings seem to be consistent with other
reports. In a UK study, patients with compensated
cirrhosis reportedly had a nearly 5-fold increased risk
of death, whereas those with decompensated cirrhosis
had a nearly 10-fold increased risk, compared with the1824general population. Overall survival was 87%
versus 75% at 1 year, and 67% versus 45% at
5 years, for patients with compensated and decom-
pensated cirrhosis, respectively.11 Given the difference
in risk of mortality and survival rates between
compensated and decompensated cirrhosis, patients
and health care providers should have a clear
understanding of distinctions between the 2
stages.18,22,23
Other tools for assessing CLD severity and prog-
nosis have been used for decades. The extent of
cirrhosis is subclassiﬁed into 4 or 5 stages with
varying prognoses, each deﬁned clinically by the
presence or absence of select complications
(Figure 2).18,24–26 The Child–Pugh (or Child–Tur-
cotte–Pugh) scoring system and the Model for End-
Stage Liver Disease (MELD) score are used to help
characterize patient prognosis.16 Rather than deﬁning
a distinct stage of cirrhosis, these scoring systems help
determine the degree of hepatic dysfunction.
Developed in the 1970s, the Child–Pugh (or Child–
Turcotte–Pugh) scoring system was originally devised
to assess mortality risk in patients with cirrhosis
undergoing portosystemic shunt surgery to prevent
variceal bleeding.27 Scoring is based on bilirubin and
albumin concentrations, the international normalized
ratio (INR), and the presence and severity of ascitesVolume 37 Number 8
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Figure 2. Stages of cirrhosis, based on presence or absence of select complications.26 One-year mortality rates
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classiﬁcation of cirrhosis as grade A, B, or C, ranked
by worsening prognosis, and scores have been shown
to correlate with the frequency of postoperative
complications, including renal failure, HE, bleeding,
infection, intractable ascites, and worsening liver
failure.28 Two older retrospective studies of patients
with cirrhosis undergoing major abdominal surgery
reported mortality rates of 10%, 30%, and 76% to
82% associated with cirrhosis grades A, B, and C,
respectively.29,30
The MELD score roughly corresponds to the
Child–Pugh score but excludes the subjective assess-
ments of ascites and HE, which may lead to interob-
server variability.31,32 The MELD score is also
reported on a continuous scale, in contrast to the
Child–Pugh score, which assesses severity within 10
levels of difference between the least sick and sickest
patients.33 The MELD score is calculated from the
natural logarithms of the serum concentrations of
bilirubin and creatinine and INR, with higher scores
indicative of worsening prognosis.31,34 Although orig-
inally designed to predict mortality in patients who
had undergone posttransjugular intrahepatic porto-
systemic shunt (TIPS), the MELD score wasAugust 2015successfully applied to predict 3-month mortality in
patients awaiting liver transplantation.31 It is therefore
valuable to prioritize liver transplant candidates by
using a “sickest-ﬁrst” policy, which is aimed at
lowering mortality among waitlisted patients. MELD
scores also provide information about prognosis, such
as short-term prognosis for noncritically ill patients
with cirrhosis.34
Diagnosis
Prevention of cirrhosis and the use of early inter-
vention strategies once it develops are vital to main-
taining patients in a symptom-free state and delaying
decompensation, thus improving outcomes.9 How-
ever, a major challenge in the diagnosis of cirrhosis
is early identiﬁcation of CLD. Most forms of CLD are
quiescent until the disease has progressed to a later
stage. Therefore, health care providers should remain
vigilant and adopt a low threshold when CLD is
suspected. A 2013 pilot study investigated the
feasibility of screening for undiagnosed CLD in a
primary care setting. Using transient elastography
(a noninvasive technique for measuring liver ﬁbrosis),
asymptomatic CLD was detected in 5.7% of subjects in
a randomly selected general population.351825
Clinical TherapeuticsIdentifying the etiologic factor in CLD is important,
as successful management of the underlying disease
(eg, antiviral treatment for HCV) can prevent addi-
tional liver injury.32 Indeed, the new era of antiviral
therapies has been transformational with respect to
achieving high cure rates (sustained virologic response
[SVR]) for the underlying condition.36–39 Early studies
with interferon alfa plus ribavirin demonstrated the
long-term beneﬁt of achieving SVR in patients with
compensated liver cirrhosis.40,41 In patients with
compensated hepatitis C–related cirrhosis, SVR was
associated with a signiﬁcant reduction in hepatocel-
lular carcinoma (HCC)-related mortality.40 Similarly,
in patients with cirrhosis and portal hypertension,
SVR was associated with fewer liver disease events
than in nonresponders (6.2% vs 38.3%, respectively;
P ¼ 0.03).41 By arresting or reversing hepatitis disease
progression, patients may also be removed from the
liver transplantation list.
Introduction of pegylated interferon marked a step
forward in achieving higher overall SVR rates.42
However, there were few options for patients with
decompensated liver cirrhosis, with interferon
contraindicated in this patient population.37 Recent
reviews on the topic of hepatitis C treatment cite
extraordinary success rates (ie, SVR rates of 90%–
100%) with interferon-free regimens containing nu-
cleoside/nucleotide analogues (eg, sofosbuvir) alone or
in combination with other direct-acting antiviral
agents.36–39 In many cases, these newer regimens are
of shorter duration than interferon-based regimens,
with the potential for combination therapies in the
future being r8 weeks in duration.38 Similar to the
potential beneﬁts observed with antivirologic
therapies for hepatitis C, treatment of hepatitis B
infection with interferon or nucleotide/nucleoside
regimens has been shown to reduce the risk of HCC,
improve the level of liver ﬁbrosis, and reverse
advanced ﬁbrosis/cirrhosis in some cases.43
Highly effective treatments that reduce downstream
liver disease events (eg, transplantation, HCC) provide
a compelling rationale for identifying appropriate
patients for treatment. Currently, screening for cir-
rhosis risk is only recommended in patients with
speciﬁc etiologic risks (eg, hepatitis). In 2012, the
Centers for Disease Control and Prevention recom-
mended that all Americans born between 1945 and
1965 be tested for HCV infection.44 Furthermore, the
Centers for Medicare & Medicaid Services will now1826cover HCV infection screenings for high-risk subjects
in this age group when ordered by the individual’s
Medicare-eligible PCP or practitioner, within the
context of a primary care setting.45 Screening for
NAFLD, which is also an etiologic factor in the
development of cirrhosis, in high-risk patients (eg,
obese, diabetic) is currently debated and not yet
recommended by hepatologic and gastroenterologic
professional associations due to lack of knowledge
related to the long-term beneﬁt and cost-effectiveness
of such screening.46
In the clinical setting, cirrhosis should be suspected
in a patient with CLD who presents with abnormal
liver function test results and abnormal serum alanine
and aspartate transaminase (ALT/AST) levels, alkaline
phosphatase levels, or bilirubin values.47 It should be
noted that although abnormal transaminase values are
common in CLD, they may be normal in patients with
cirrhosis.32 Therefore, although most patients with
CLD will present with abnormal liver test results,
health care providers should consider the diagnosis of
CLD if other signs or symptoms are present in patients
with normal liver test results.
Unfortunately, health care providers often miss the
opportunity for early detection and treatment of
cirrhosis when they focus solely on abnormalities in
laboratory values. Indeed, 1 study revealed that in at
least 10% of patients in the primary setting who had
abnormal liver function test results, there was insufﬁ-
cient investigation/follow-up, and referrals/diagnoses
were missed.48 A low platelet count might also be a
marker of cirrhosis47 and is generally the result of
platelet sequestration in the spleen as a result of portal
hypertension. Therefore, if present in a patient who
has, or is at risk of, liver disease, further evaluation
may be warranted. Noninvasive markers (eg, the AST-
to-platelet-count ratio index [APRI], the Fibrosis-4)
use routine laboratory tests in their calculations and
may also be helpful in the evaluation of patients with
CLD to determine if they have advanced ﬁbrosis.49,50
Patients with suspected cirrhosis can also be examined
for evidence of so-called “CLD stigmata,” such as
vascular spiders, palmar erythema, and muscle wast-
ing.51,52 A palpable left liver lobe, hepatomegaly, and
splenomegaly may also be suggestive of cirrhosis.52
Staging of Hepatic Fibrosis
Progressive hepatic ﬁbrosis can lead to cirrhosis,
making its early detection important. Furthermore,Volume 37 Number 8
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etiologic factor is removed.53,54 Liver biopsy is the
gold standard for the diagnosing and staging of
ﬁbrosis, providing information on the degree of
ﬁbrosis as well as other concomitant processes. Never-
theless, despite its many beneﬁts, liver biopsy has a
number of limitations, including invasiveness, cost,
poor patient acceptance, and risk of complications.55
A number of ﬁbrosis staging systems exist, which
vary according to the underlying disease. The META-
VIR system (developed by Metavir, group of pathol-
ogists in France that formed to discuss scientiﬁc
problems related to hepatitis C) comprises 5 stages:
F0, no ﬁbrosis; F1, portal ﬁbrosis without septa
(minimal ﬁbrosis); F2, portal ﬁbrosis with few septa
(moderate ﬁbrosis or clinically signiﬁcant ﬁbrosis); F3,
septal ﬁbrosis with many septa but no cirrhosis (severe
ﬁbrosis); and F4, cirrhosis.55 Another system, the
Brunt criteria, was developed for evaluating patients
with NAFLD and uses separate assessments for grade
of hepatic necroinﬂammation and stage of ﬁbrosis.56
Building on the Brunt classiﬁcation, the Clinical
Research Network in Nonalcoholic Steatohepatitis
has developed a scoring system that evaluates
nonalcoholic steatohepatitis, the progressive form of
NAFLD, by producing a single score (the NAFLD
activity score).56,57 The presence and extent of ﬁbrosis
can also be estimated indirectly by using biomarkers
of ﬁbrosis (eg, FibroSURE assay [Laboratory Corpo-
ration of America Holdings, Burlington, North Caro-
lina], which has a sensitivity and speciﬁcity of 85%
and 72%, respectively)32; however, other noninvasive
assessments (eg, APRI, Fibrosis-4 scores) offer alter-
natives to these commercial markers and use standard
laboratory tests in their calculations.49,50
A substantial number of noninvasive imaging and
laboratory-based tests have also been developed for
the diagnosis and staging of liver ﬁbrosis, many of
which have been reviewed by Gonzalez et al58 and
Kim et al.59 Brieﬂy, the most widely used are elas-
tographic techniques, which measure the mechanical
property (ie, stiffness) of the liver by transmitting
waves into the liver parenchyma and summarizing the
pattern of wave propagation.55 One of these tech-
niques, transient elastography (FibroScan [Echosens,
Paris, France]), was approved in the United States in
2013 and is a good predictor of disease stage,
providing sensitivity between 72% and 84% and
speciﬁcity between 82% and 95%; however, the testAugust 2015is not widely available.60,61 Acoustic radiation force
impulse elastography is another noninvasive imaging
technique used for ﬁbrosis assessment, which is as
efﬁcient as transient elastography in diagnosing severe
ﬁbrosis and/or cirrhosis in patients with CLD.62
Magnetic resonance elastography can identify
patients at risk for decompensation; however, it is
available only in a small number of centers.63
Ultrasound, computed tomography, and magnetic
resonance imaging are additional noninvasive
imaging techniques that have been applied with
varying degrees of success.
Beyond imaging modalities, there are several sim-
ple, noninvasive laboratory-based tests, including the
APRI, the AST/ALT ratio, the Lok score, the Göte-
borg University Cirrhosis Index (GUCI), the Cirrhosis
Score University of Naples score, and the ﬁbrosis
index.64–67 The APRI is a test that was validated in
patients with hepatitis C; however, similar to Fibro-
Scan, this test may not be as useful in assessing the
early stages of ﬁbrosis.68 The Lok score uses platelet
count, AST/ALT ratio, and prothrombin INR to
predict histologic cirrhosis.65 A similar test (GUCI)
using 3 of the 4 inputs (AST, platelet count,
prothrombin INR) that comprise the Lok score was
developed by a Swedish group.69 The Cirrhosis Score
University of Naples test uses the same inputs as GUCI
but with the addition of patient age.67 Another
laboratory test, the ﬁbrosis index, was derived from
measurements of platelet count and serum albumin in
patients with hepatitis C. This test has shown
acceptable accuracy in the assessment of liver disease
progression.70 In general, these tests have proven to be
useful in assessing ﬁbrosis/cirrhosis, but all have some
limitations and may replace liver biopsy only in select
patients.58,64
Complications of Cirrhosis
Portal Hypertension
Development of portal hypertension represents a
hallmark in the clinical course of cirrhosis. It is often
the earliest consequence of cirrhosis, and it underlies
many of the other complications of the disorder
(Figure 3).71 Portal hypertension is deﬁned as a
pathologic increase in portal venous pressure;
speciﬁcally, it is an increase in the hepatic venous
pressure gradient (HVPG) across the liver to levels
exceeding 5 mm Hg.71 Clinically signiﬁcant portal
hypertension is deﬁned as an HVPG Z10 mm Hg,1827
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Figure 3. The role of portal pressure in the development of cirrhosis.71 HVPG ¼ hepatic venous pressure
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Clinical Therapeuticsand an elevated HVPG is an independent predictor of
the development of decompensated cirrhosis, in
addition to serum albumin levels or MELD
score.72,73 Over a mean follow-up period of 4 years
in patients with compensated cirrhosis, those with
lower HVPG (o10 mm Hg) were found to have a
90% probability of not progressing to the decom-
pensated stage.72 Data suggest that a 3% increase in
risk of mortality occurs with every increase in HVPG
of 1 mm Hg.74
Management of portal hypertension remains chal-
lenging. A randomized, double-blind, placebo-con-
trolled, multisite trial in patients with cirrhosis and
portal hypertension (deﬁned in the study as HVPG
Z6 mm Hg) but no complications, reported no beneﬁt
versus placebo from “preprimary” prophylactic treat-
ment with a nonselective β-blocker given to prevent
the development of complications.75 At present, no
speciﬁc treatments are recommended for patients at
this early stage of the disease; instead, the manage-
ment strategy is to treat the underlying etiologic
factors of cirrhosis in an effort to reduce the
hypertension.76,77Variceal Bleeding
As portal pressure increases, veins in the esophagus
and stomach dilate and form varices (ie, esophageal
varices, gastric varices), which can hemorrhage as a
result of the increased portal pressure. Esophageal
varices are more common than gastric varices. Varices1828tend to form at portal pressures Z10 mm Hg and
occur in 50% of patients with cirrhosis.78 They are
asymptomatic, but once ruptured, they require
emergency care and, despite progress in treatment,
variceal bleeds carry a 20% mortality risk at 6
weeks.18,76,78 Treatment of variceal hemorrhage in-
cludes infusion of vasoactive agents along with endo-
scopic intervention (eg, band ligation for esophageal
varices, variceal obliteration for gastric varices),79
administration of nonselective β-blockers (eg, carvedi-
lol), placement of TIPS (particularly in subjects
with recurrent variceal bleeding), and use of anti-
biotics (eg, quinolone, ceftriaxone) for the treatment
of infection.80,81
Because it remains unclear whether variceal bleed-
ing precedes infection or infection precipitates bleed-
ing, it is appropriate to administer antibiotics as a
standard practice.82 Current guidelines recommend
primary prophylaxis only for patients at high risk of
bleeding, with nonselective β-blockers and band liga-
tion considered similarly effective.76,83 Secondary
prophylaxis, with a combination of medication and
endoscopic treatment (eg, β-blocker plus band liga-
tion), is recommended as ﬁrst-line therapy to prevent
rebleeding.78Ascites and Spontaneous Bacterial Peritonitis
Ascites (an accumulation of ﬂuid in the peritoneal
cavity) results when portal hypertension causes
splanchnic vasodilation and activation of theVolume 37 Number 8
A.J. Muirrenin–angiotensin–aldosterone system, which culmi-
nates in sodium and water retention. The accumulation
of ﬂuid results in abdominal swelling and is associated
with bloating and pain. Ascites is a marker of decom-
pensation, and it develops in 50% to 60% of patients
within 10 years of a cirrhosis diagnosis.21 Refractory
ascites, deﬁned as ascites that does not recede or that
recurs soon after therapeutic intervention, is less
common but has a predicted survival rate as low as
32% to 52% at 1 year, with prognosis worsening in the
presence of hepatorenal comorbidities.84,85 Treatment
(eg, diuretics plus dietary salt restrictions) is generally
not curative but may improve patient quality of life and
decrease the risk of secondary complications, such as
spontaneous bacterial peritonitis (SBP).86–88 TIPS is
indicated for patients with refractory ascites, although
referral for transplantation is also considered.88
Spontaneous bacterial peritonitis is a complication of
uncontrolled ascites that occurs when the body’s natural
bacteria enter ascitic ﬂuid, causing infection. Typically, it
is diagnosed by a polymorphonuclear cell count 4250
cells/mL. Gram stain/culture can also be used to make
the diagnosis, but it has a low sensitivity for detecting
SBP,89 and clinicians should not wait for results to
initiate empiric therapy with broad-spectrum antibiotics
in patients with signs and symptoms of infection.86
Indeed, use of antibiotics for primary prophylaxis is
recommended in some cases of advanced disease, and
secondary prophylaxis (after an episode of SBP) should
always be used.86 Hospitalized patients should receive
antibiotics within 6 hours and ambulatory patients
within 24 hours of presentation with suspected SBP.32
Hepatic Encephalopathy
HE is a potentially reversible condition associated
with neuropsychiatric symptoms and neuromuscular
dysfunction of varying severity.90,91 It represents a
spectrum of abnormalities that range from minimal
HE (subtle alteration in cognitive function determined
via neuropsychometric tests) to overt HE (clinical
symptoms, such as generalized motor dysfunction
with alterations in consciousness). The exact patho-
genesis of HE is not fully understood, although it has
been hypothesized that gut-derived toxins (eg, ammo-
nia) play a role.92 Gut-derived substances escape
hepatic clearance, due to parenchymal liver failure
or portosystemic shunting, and reach the systemic
circulation where they can exert toxic effects on the
brain. A number of factors, including infection andAugust 2015electrolyte disturbances, can elicit an overt HE episode
and should be treated to gain control of the episode.93
However, the presentation of HE demonstrates
progression to decompensated cirrhosis and the need
for long-term treatment and monitoring to prevent
recurrence.94 The ﬁrst goal of treatment for HE is to
identify and cure the underlying condition that has
precipitated HE (eg, infection). In addition to
addressing the underlying causes, nonabsorbable
disaccharides and minimally absorbed antibiotics are
commonly administered for the treatment of overt
HE.91 Lactulose, a nonabsorbable disaccharide, is
recommended as a ﬁrst-line treatment option for
patients with an overt HE episode and to prevent its
recurrence.93 However, lactulose is poorly tolerated,
and thus there is a risk for nonadherence.95 Rifaximin
is a nonsystemic antibiotic that is well tolerated and
efﬁcacious as an add-on therapy to lactulose for the
prevention of HE recurrence.91,93
Hepatorenal Syndrome
Renal function is affected in patients with advanced
cirrhosis and, as such, it is an integral component of
the MELD score (estimated by using serum creatinine
levels). Hepatorenal syndrome is caused by progres-
sive systemic arterial vasodilation, particularly in the
splanchnic bed, resulting in reduced arterial blood
volume and activation of sodium-retentive mechanisms
and intrarenal arterial vasoconstriction. Hepatorenal
syndrome is a potentially reversible complication of
cirrhosis that is associated with a rapid deterioration of
kidney function in the absence of intrinsic kidney
disease but often with poor prognosis and high mortal-
ity.91 It can be categorized as type 1 (rapid decline in
renal function with a mortality rate of 50% at o1
month) or type 2 (steady decline in renal function with a
mortality rate of 50% at 4 to 6 months).96 Due to the
role of arterial vasodilation in the pathogenesis of
hepatorenal syndrome, vasoconstrictors are adminis-
tered, but despite their use, patient prognosis remains
poor.91,97,98
Hepatocellular Carcinoma
Accounting for 490% of all cancers of the liver,
HCC is the leading cause of death in patients with
cirrhosis, and in 480% of cases, its management is
complicated by the underlying cirrhosis.6,99,100 The
age-adjusted incidence rates of HCC tripled in the
United States from 1975 to 2005 (mostly as a1829
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Figure 4. Algorithm for the management of complications of cirrhosis.32 In patients with advanced disease (not
shown in the figure), the use of intravenous antibiotics in conjunction with intravenous albumin has
been shown to reduce the incidence of renal impairment and mortality compared with antibiotics
alone.104 Adapted with permission from Starr SP, et al. Am Fam Physician. 2011;84:1353-1359.32
Clinical Therapeuticsconsequence of HCV-related cirrhosis).101 Data
indicate that portal hypertension is an independent
predictor of HCC development, with HVPG410 mm
Hg associated with a 6-fold increase in HCC risk.72
Current guidelines recommend that patients at risk for
HCC undergo ultrasound-based surveillance at 6-
month intervals (α-fetoprotein determination is no
longer recommended).99,102
Multimodal Management of Cirrhosis
Management guidelines for cirrhosis and its compli-
cations are based on a large body of high-quality
evidence from numerous randomized controlled trials
and meta-analyses (Figure 4).32,52,103,104 CLD is a
challenging condition to manage and is characterized1830by frequent, prolonged, and costly hospital readmissions.
In 1 study, 69% of patients (N = 402) had Z1
readmission, with 14% readmitted within 1 week and
37% within 1 month.105 In the context of relatively high
rates of hospitalization, it is not surprising that patient
care varies among health care providers, with
appropriate coordination of care between PCPs and
specialists generally regarded as limited and with room
for improvement.103 As in the management of any
chronic disease state, an opportunity exists to reduce
the number of patients who are hospitalized or
readmitted for cirrhosis-related complications. In a cohort
of the aforementioned study of patients with decompen-
sated cirrhosis, 22% of 165 readmissions within 30 days
of discharge were considered preventable.105Volume 37 Number 8
Chronic care model
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Figure 5. Improving the management of cirrhosis: a conceptual model.103 EHR ¼ electronic health record.
Reprinted from Clin Gastroenterol Hepatol, vol. 11, no. 3: Mellinger JL, Volk ML, Multidisciplinary
management of patients with cirrhosis: a need for care coordination, pg. 217-223. Copyright 2013,
with permission from the AGA Institute.103
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strategy for improving outcomes in patients with
cirrhosis is achieved when a multidisciplinary, inte-
grated approach between specialists and PCPs is
adopted.52,103,106,107 To improve the quality and
efﬁciency of care in patients with cirrhosis and move
toward a uniﬁed and multidisciplinary approach, a
number of improvements to the current models of care
are needed (Figure 5).103 Proposed strategies include
active management between visits/telemedicine (ie,
chronic care model); coordination between medical
specialties (eg, colocation within a single clinic);
and improvement in communication and delineation
of responsibilities (and time taken) between special-
ists and generalists (eg, electronic health records,
e-referrals).103 The focus of the chronic care model
is to keep patients actively engaged between clinic
visits, whether using home visits, telephone calls, and/
or mailings. Of these techniques, home-based inter-
ventions seemed to provide the greatest beneﬁt in a
study of heart failure patients.108 In addition to
keeping patients actively engaged in the management
of cirrhosis, multidisciplinary care should include a
gastroenterologist/hepatologist, PCP, and other
potential specialists (eg, radiologist, endocrinologist,
infectious disease specialist, psychiatrist). Importantly,
coordinating communication between practitioners is
a vital strategy to help ensure quality and efﬁciency
of care.103August 2015Looking more speciﬁcally at roles and responsibil-
ities, PCPs can play a key role in the identiﬁcation of
patients at risk for or symptomatic of CLD, and in the
collaborative management and prevention of cirr-
hosis-related complications. Because PCPs are the ﬁrst
medical contact for the majority of patients, they must
be able to recognize potential diagnoses as early as
possible and manage patients appropriately by using
treatments that are supported by guidelines and high-
quality evidence.52,103,107 The only deﬁnitive cure for
cirrhosis is liver transplantation. The severity of the
liver disease, assessed by using MELD or Child–Pugh
scores and the development of complications, deter-
mines when a patient should be referred for liver
transplantation.109,110 Health care providers, includ-
ing PCPs, should be educated to facilitate timely
referral, and they must be able to recognize essential
turning points at which a patient may become eligible
for a transplantation referral.109,110
Chronic disease management programs have met
with success in other chronic disease areas, including
heart disease and diabetes. A pilot study applying such
a model to patients with chronic liver failure did not
seem to reduce hospital admission rates or disease
severity or to improve patient quality of life. However,
some beneﬁts were observed (eg, signiﬁcant increases
in outpatient attendance), and the authors concluded
that larger trials with longer follow-up periods were
warranted.111,112 A 2013 study has shown the beneﬁts1831
Clinical Therapeuticsof an integrated management approach to CLD care.
The “care management check-up” model of specialized
caregiving reported signiﬁcant reductions in mortality
and hospital readmissions in outpatients allocated to
the integrated management scheme versus standard
outpatients. Global health care costs were also reduced
as a result of a more rational use of hospital services.
Clearly, the application of such models to CLD
management warrants further investigation.
CONCLUSIONS AND FUTURE DIRECTIONS
A key component in the management of patients with
cirrhosis is the treatment and prevention of associated
complications.16,113 In addition to treating the under-
lying disease leading to cirrhosis, early intervention
and ongoing surveillance for cirrhosis-related compli-
cations are critical to outcomes and patients’ quality
of life. A major challenge in the diagnosis of cirrhosis
is recognizing underlying liver disease, particularly in
its earlier stages. Health care providers should be
vigilant and adopt a low diagnosis threshold when
CLD is suspected. Patients at risk for developing
cirrhosis should be screened, and the etiologic factor(s)
identiﬁed and treated or eliminated whenever possible.
The management of patients with cirrhosis should
move toward a multidisciplinary, integrated approach
between specialists and PCPs.
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